I’m sure most are...but honestly, management doe
Post# of 72440
Where I think the company made a couple mistakes, mainly mistakes in perception which is huge with a start up, is the handling of the CRO with P results. And the handling of the MFO. The fact that the MFO hasn’t been named, looks bad. Certainly does nothing to exude investor confidence. Same with the CRO issue.
It’s my opinion that those two factors hurt the sp over the last six months more than anything.
Science is solid, I don’t believe management has any nefarious intent. But those two issues have left the company vulnerable and in turn, shareholders.
That’s how I see things.